June 28 (Reuters) - Boston Scientific Corp. and CryoCor Inc. said they entered a deal to co-develop therapies for atrial fibrillation -- abnormal beating of the heart's upper chambers. CryoCor's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback